Andrew Zhu, MD, PhD

Andrew X. Zhu, MD, PhD, professor of medicine at the Harvard Medical School and director of Liver Cancer Research at the Massachusetts General Hospital Cancer Center, discusses the evolving treatment landscape for patients with hepatocellular carcinoma (HCC).

For patients with advanced HCC, sorafenib (Nexavar) dominated the field for many years, according to Zhu. The multi-targeted tyrosine kinase inhibitor (TKI) lenvatinib (Lenvima) later joined the field as an alternative single-agent treatment option for patients with advanced HCC. This provided a second option for the frontline setting, and for a long time, clinical trials were unable to demonstrate better activity with other agents or regimens than single-agent sorafenib.

The combination of atezolizumab (Tecentriq) plus bevacizumab (Avastin) was able to demonstrate superiority compared with sorafenib in terms of overall survival more recently, and the combination received approval in May 2020.

Videos

Andrew X. Zhu, MD, PhD, discusses the evolving treatment landscape for patients with hepatocellular carcinoma.

Exploring the Evolving Treatment Landscape for Advanced Hepatocellular Carcinoma

Andrew Zhu, MD, PhD, director of Liver Cancer Research and Medicine at Massachusetts General Hospital, shares his advice on making decisions for frontline treatment of patients with hepatocellular carcinoma (HCC).

According to Zhu, most clinicians base these decisions off the best available data. If the overall survival (OS) difference is available, that will guide clinicians in choosing one agent over another.

Andrew Zhu, MD, PhD, director of Liver Cancer Research and Medicine at Massachusetts General Hospital, shares his advice on making decisions for frontline treatment of patients with hepatocellular carcinoma.

Andrew Zhu, MD, PhD | Authors

Articles

Exploring the Evolving Treatment Landscape for Advanced Hepatocellular Carcinoma

Advice on Decision Making for Frontline Treatment of HCC